Account
Baxter International Inc. (BAX) said results from a late-stage study of its potential treatment for Alzheimer's, immunoglobulin, were negative.The results didn't meet the co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.Baxter--which makes medical products for people with bleeding, kidney and immune disorders, among other conditions--said it will reconsider its current approach for its Alzheimer's program and will determine next steps after full data analyses. Current Baxter studies of immunoglobulin in mild to moderate Alzheimer's disease will be discontinued.Top-line analyses from the randomized, double-blind, placebo-controlled, multicenter trial found that after 18 months of treatment, patients with mild to moderate Alzheimer's disease taking Baxter's immunoglobulin treatment didn't demonstrate a statistically significant difference in the rate of cognitive decline as compared with placebo. ...
Inspiration Biopharmaceuticals Inc. reached a deal to sell its second development-stage hemophilia drug at auction Tuesday to Cangene Corp. for $5.9 million in cash ...
Investor AB (INVE-B.SK), the Swedish investment company, Tuesday posted a 12% on-year rise in net asset value per share and raised its dividend, adding that it aims ...
FBN’s Diane Macedo breaks down the stories moving the markets around the world.
Baxter International Inc. (BAX) posted a 6.7% rise in fourth-quarter earnings as the company's focus on life-saving therapies continued to drive sales.The medical-pr...
Cyberonics CEO Daniel Moore on the impact of the medical device tax on jobs and patient care.
Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.The medical product c...
Healthcare products maker Baxter International Inc said on Tuesday that it would buy privately held Swedish dialysis product company Gambro AB for about $4 billion t...
U.S. stock indexes fell modestly Tuesday as U.S. political leaders readied for more budgets talks to avert steep tax hikes and spending cuts that could push the econ...
FOX Business brief: Late-morning markets
Baxter International Inc said on Tuesday that it would buy privately held Swedish dialysis product company Gambro AB for about $4 billion to complement its kidney th...
U.S. stock indexes were little changed Tuesday as U.S. political leaders readied for more budgets talks to avert steep tax hikes and spending cuts that could push th...
Baxter International Inc said on Tuesday that it would buy privately held Swedish dialysis product company Gambro AB for about $4 billion to complement its kidney th...
The spike late last year in doctor and hospital visits apparently lasted as long as the flu.After years of decelerating health-care usage--linked to economic problem...
Baxter International Inc. (BAX) reported a slight increase in first-quarter sales, as growth in emerging markets helped to offset continued pricing and utilization p...
Baxter International Inc.'s (BAX) first-quarter earnings fell 11% as the medical-products company was hurt by acquisition-related charges and the year-earlier period...
The U.S. stock market closed out a choppy week with a gain as policymakers in Cyprus were in talks with EU officials to secure a bailout for the Mediterranean island...
Gentium SpA (GENT) said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion, recommending the refusal of marketi...
In the past year, defense company SAIC Inc has shrunk the office space it either owns or leases by 306,000 square feet (28,428 sq meters), the size of about five foo...
CSL Ltd. (CSL.AU), one of the world's biggest manufacturers of blood plasma and flu vaccines, said Wednesday its first half profit rose 24% as it capitalized on a ri...
